241 - 252 of 7717 results
0.5 CME CREDIT

Triglycerides and their management have received a great deal of publicity recently due to clinical trial results. Join Dr. Ty Gluckman as he reviews the risks associated with hypertriglyceridemia, discusses available therapeutic options to lower triglycerides, and reconciles the finding of the REDUCE-IT and the STRENGTH trials.


1 CME CREDIT

Ophthalmology emergencies in primary care can have profound consequences, and ruling out urgent referrals can be challenging. This session will provide you with a toolbox of tips and strategies to help triage urgent ophthalmic conditions in your practice.


ember spark background
1 CME CREDIT

Practice-changing updates to the medical literature that are hot off the presses! Join Dr. Pam Kushner to discuss important changes in the 2021 ADA guidelines and examine recently published research on atrial fibrillation, lipids, reducing cardiovascular risk, coconut oil, patient communication, and much more!


1 CME CREDIT

What happens when your patient does not respond to a SSRI? What happens when you try a second or third medication to treat depression and it still does not help? This course will review how to manage these more challenging cases of depression that are all too common in primary care settings.


Young black male wearing a mask
1 CME CREDIT

Is Racism a Public Health Crisis?

Episode 14: Bridging the Gap: Conversations with Dr. Hall

1.00 CME

The past few years have brought a refreshing focus to the interplay of racism and health outcomes in the United States. Now communities across the country are declaring racism a public health crisis, but why and what does this mean? In this session Dr. Gregory Hall walks us through the data on why US communities have declared racism a public health threat. He will explore the history behind these declarations and review how you as a clinician can have an impact on this health crisis.


1 CME CREDIT

COVID-19 Vaccines: Science vs. Anti-Science

Featuring Peter J. Hotez, MD, PhD

1.00 CME/MOC
1.00 AANP | 0.40 Pharmacology

Globally, we are seeing a mixed picture of vaccinating the United States and the world against COVID-19, with tremendous progress containing the B.1.1.7 variant in the United States but failing to control widespread transmission in Africa and Latin America. Dr. Hotez will discuss the progress made to date with the US vaccination program, what we can expect toward the end of 2021 and into 2022, and how we can advance vaccinations globally. This session will also explore the impact of a rising and shifting anti-vaccine movement.


1 CME CREDIT

Hot Topics in Pediatrics

1.00 CME/MOC
1.00 AANP | 0.25 Pharmacology

This presentation will highlight recent developments and controversies in the pediatrics field by utilizing case-based discussions, and reviewing current evidence-based guidelines. Among the topics discussed, emphasis will be placed on the appropriate selection of antibiotics for common skin and soft tissue infections in the era of bacterial resistance. Additionally, this session will include a review of the impact that COVID-19 has had in the pediatric population, and the potential hesitancy that providers will encounter once a pediatric COVID-19 vaccine becomes available.


0.5 CME CREDIT

With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss the most common reactions to the two approved COVID-19 mRNA vaccines, as well as evaluate the data on the efficacy of zinc and vitamin C on outpatients and single high dose of vitamin D among inpatients with SARS-CoV-2 infection.


Close up of man holding his knee in pain
1 CME CREDIT

Fatty liver has emerged as a major health concern in the United States. It is now one of the leading causes of cirrhosis, risk factor for liver cancer and indication for liver transplantation. This session will help clinicians to understand the epidemiology and risk factors of fatty liver as well as how to tailor medical care in patients with underlying fatty liver disease.


1 CME CREDIT

In this presentation on Lyme and other tickborne diseases, Dr. Solomon will review the clinical approach to patients with suspected tickborne disease. He will focus on a comprehensive review of Lyme disease including the clinical manifestations, the challenges and pitfalls in diagnostic testing, prevention of Lyme through the use of post-exposure prophylaxis, and the potential co-infections carried by the same vector. He will review the evidence on management of Post-Treatment Lyme Disease Syndrome and offer a rational approach to treatment. Finally, he will discuss the social controversy around “Chronic Lyme.”


1.5 CME CREDITS

Human beings have understood the effects of chronic obstructive pulmonary disease (COPD) for centuries. Dozens of medications and interventions have been approved and prescribed to combat these diseases, and treatments strategies have been developed that depend largely on severity of symptoms and disease staging. In this discussion, Dr. Devarajan will review the staging of COPD and how staging ties into optimal treatments. We will also spend some time reviewing useful prognostic scores, lung cancer screening practices in 2021, and the approach to the breathless patient. Dr. Kumar will focus on the topic of essential basics of interstitial lung diseases for the community of physicians and other clinical healthcare professionals. This will include an overview of various types of interstitial lung diseases with brief discussion on clinical features and radiographic features that distinguish them from each other. This presentation will also highlight some of the newer therapies and advanced treatment options.


1 CME CREDIT

Alcohol use frequently co-occurs with anxiety disorders, especially during the highly anxiety-provoking circumstances of the current pandemic. People increasingly self-medicate their stress with alcohol, sometimes leading to frank alcohol use disorder. Despite alcohol’s legal status and social acceptability in many countries, it remains a potentially dangerous, toxic substance. Withdrawal from alcohol can be fatal, and medically managed withdrawal is often necessary to ensure patient safety. In this presentation, we will describe the fundamental pharmacology and acute presentations of alcohol use disorder and discuss counseling approaches. We will then explore the clinical aspects of the three FDA-approved medications for its treatment: disulfiram, naltrexone, and acamprosate. We will conclude with some novel ideas about future directions in the pharmacotherapy of alcohol use disorders.